Background/aims: The results of hepatic surgery for colorectal metastases are distorted by the high incidence of recurrence, despite an apparently radical resection. Selection of high-risk patients is a mandatory step towards effective application of neo-adjuvant chemotherapy. In this study, expression of the tumor suppresser gene p53 in colorectal liver metastases was correlated with recurrence after resection.
Methodology: In a retrospective case-series p53 expression was assessed using standard immunohistochemical methods in the paraffin-embedded specimens of 45 liver resections for colorectal metastases, performed in 43 patients in a single institution between '86 and '96. Hospital and office charts were reviewed and follow-up was completed with a General Physicians' questionnaire in October '97. Relapse-free and cancer-specific survival from diagnosis of hepatic metastases were assessed and compared for p53+ and p53- groups.
Results: Median survival was 36 months with an estimated 5-year cancer-specific survival of 43% (95% confidence interval 35%-51%). Relapse-free and cancer-specific survival were not significantly different between p53+ (n = 24, 53%) and p53- (n = 21) groups (P = 0.86 and P = 0.91 respectively). P53 expression was not associated with other potential predictors, which were not of predictive value either.
Conclusions: Patients at risk for recurrent disease following partial hepatectomy for colorectal metastases cannot be identified by p53 expression.